Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-site, Single Arm, Phase II Clinical Trial, to Evaluate the Efficacy of OMT-111 in Supporting the Treatment of Terminal Stage Solid Tumors

NCT04520386 is registered in ClinicalTrials.gov with MetiMedi Pharmaceuticals as lead sponsor.

NCT NCT04520386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04520386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-site, Single Arm, Phase II Clinical Trial, to Evaluate the Efficacy of OMT-111 in Supporting the Treatment of Terminal Stage Solid Tumors
Lead sponsor
MetiMedi Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2020
Completion date
October 31, 2022
Enrollment
78 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lung cancer, pancreatic cancer